Isofol Medical AB today announced that the Swedish Medical Products Agency has approved the use of Isofol Medical's newly produced vials of Modufolin® for clinical trials. This enables Isofol Medical to initiate its first clinical trial on humans, the LARS2 trial. The LARS2 trial offers proof of concept of Modufolin® in combination with antifolates for neoadjuvant treatment of rectal cancer patients. It is performed in collaboration with Sahlgrenska University Hospital.
”We are very pleased by this regulatory approval as access to new Modufolin® vials enables us to directly initiate the already approved LARS2 trial. Isofol would like to thank both Unitech Pharma and Merck & Cie for their strong efforts throughout the manufacturing process” said Anders Rabbe, Isofol Medical’s CEO.
As a first step, 3000 vials of Modufolin® have been manufactured in December 2010 at Unitech Pharma’s plant in Matfors, Sweden. This batch will now be released. An additional 6000 vials will be manufactured and released during March 2011. These two batches will fulfill Isofol Medical’s pre-clinical and clinical requirements of Modufolin® until 2013.
For more information, please contact: Anders Rabbe, CEO, Isofol Medical AB
E-mail: firstname.lastname@example.org Phone: +46 (0)707 646 500
Isofol Medical is based on 30 years of medical research which has resulted in the novel folate-based pharmaceutical product Modufolin®. Modufolin® is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. Isofol works closely with its strategic Swiss R&D partner Merck & Cie, the world’s leading manufacturer of reduced folates. In parallel to the drug development, Isofol Medical is performing diagnostic research to personalize and optimize the use of folate-based therapies for cancer treatment.